- All Drug Categories
- Home
- Anti-cancer Drugs
- Healthcare Products
- Medical Information
- Statement
The duration of medication for Adagrasib needs to be dynamically adjusted according to individual patient conditions. Clinical data shows a med...
The medication cycle of Relugolix should be determined based on the treatment indication and patient response. It is usually used for chronic d...
Relugolix, as a novel GnRH receptor antagonist, has demonstrated rapid and sustained testosterone inhibition in the treatment of prostate cance...
Futibatinib, as a highly selective FGFR inhibitor, has shown significant efficacy in solid tumors such as cholangiocarcinoma carrying FGFR2 gen...
Futibatinib, as a highly effective inhibitor targeting FGFR2 gene mutations, has shown excellent clinical efficacy in the treatment of solid tu...
Capasertib is a new AKT kinase inhibitor, which plays an anti-tumor role by targeting the inhibition of PI3K/AKT/mTOR signaling pathway. At pre...
As an AKT kinase inhibitor, the clinical application of Capivasortib requires strict adherence to specific restrictions, including contraindica...
Sparsentan has not yet been approved for marketing in Chinese Mainland. Patients need to obtain the drug through overseas channels, but they ne...
Sparsentan has not been listed in Chinese Mainland and has not been included in the national medical insurance reimbursement. If patients need ...
The standard method of taking elacestrant is once daily oral administration of 345mg (four tablets of 86mg each), which should be swallowed who...
